Bristol Myers Squibb to Acquire Orbital Therapeutics

Bristol Myers Squibb announced that it will acquire Orbital Therapeutics to expand and diversify its cell therapy portfolio.

The acquisition includes Orbital’s lead RNA immunotherapy preclinical candidate, OTX-201, and its proprietary RNA platform that integrates circular and linear RNA engineering, lipid nanoparticle delivery, and AI-driven design to create programmable RNA therapies. “In vivo CAR T represents a novel treatment approach that could redefine how we treat autoimmune diseases,” said Robert Plenge, Executive Vice President and Chief Research Officer, Bristol Myers Squibb.

This acquisition advances the region’s position in cell and gene therapy innovation and broadens access to next-generation treatments.